Fate Therapeutics Inc (NASDAQ:FATE) appears in 139 institutional 13F filings for the quarter ending December 2025.
| Owner Name | Date | Shares Held | Change (QoQ) | Change (%) | Value (USD) |
|---|---|---|---|---|---|
| Redmile Group, LLC | 31 Mar, 2026 | 12,872,946 | 0 | 0.00% | $15,447,535.00 |
| BlackRock, Inc. | 31 Mar, 2026 | 10,068,614 | -107,873 | -1.06% | $12,082,337.00 |
| VANGUARD CAPITAL MANAGEMENT LLC | 31 Mar, 2026 | 4,192,063 | 4,192,063 | 0.00% | $5,030,476.00 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 31 Mar, 2026 | 4,134,585 | 4,134,585 | 0.00% | $4,961,502.00 |
| ACADIAN ASSET MANAGEMENT LLC | 31 Mar, 2026 | 4,120,200 | 1,188,307 | 40.53% | $4,938.00 |
| TWO SIGMA INVESTMENTS, LP | 31 Mar, 2026 | 3,466,786 | 1,732,722 | 99.92% | $4,160,143.00 |
| Johnson & Johnson | 31 Mar, 2026 | 3,379,064 | -3,379,064 | -50.00% | $4,054,877.00 |
| AQR CAPITAL MANAGEMENT LLC | 31 Mar, 2026 | 3,001,521 | 1,839,516 | 158.31% | $3,601,825.00 |
| RENAISSANCE TECHNOLOGIES LLC | 31 Mar, 2026 | 2,974,683 | 613,802 | 26.00% | $3,569,620.00 |
| GEODE CAPITAL MANAGEMENT, LLC | 31 Mar, 2026 | 2,590,429 | 122,081 | 4.95% | $3,109,189.00 |
| State Street Corp | 31 Mar, 2026 | 2,263,173 | -2,044 | -0.09% | $2,715,808.00 |
| UBS Group AG | 31 Mar, 2026 | 1,821,715 | 1,418,191 | 351.45% | $2,186,058.00 |
| Goldman Sachs Group Inc | 31 Mar, 2026 | 1,327,757 | -1,542,323 | -53.74% | $1,593,309.00 |
| TANG CAPITAL MANAGEMENT LLC | 31 Mar, 2026 | 1,167,773 | 0 | 0.00% | $1,401,328.00 |
| CITADEL ADVISORS LLC | 31 Mar, 2026 | 942,926 | 193,590 | 25.83% | $1,131,511.00 |
| DIMENSIONAL FUND ADVISORS LP | 31 Mar, 2026 | 883,790 | -693,688 | -43.97% | $1,060,068.00 |
| Irenic Capital Management LP | 31 Mar, 2026 | 878,055 | 878,055 | 0.00% | $1,053,666.00 |
| Northern Trust Corp | 31 Mar, 2026 | 811,920 | 79,250 | 10.82% | $974,305.00 |
| Monaco Asset Management SAM | 31 Mar, 2026 | 810,000 | -20,000 | -2.41% | $972,000.00 |
| Bruce & Co., Inc. | 31 Mar, 2026 | 789,188 | 60,000 | 8.23% | $947,026.00 |